Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Mcdonald Capital Investors Inc. CA's 4th Largest Position

Mcdonald Capital Investors Inc. CA grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.6% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 196,773 shares of the biopharmaceutical company's stock after acquiring an additional 26,593 shares during the quarter. Regeneron Pharmaceuticals comprises about 7.9% of Mcdonald Capital Investors Inc. CA's portfolio, making the stock its 4th biggest holding. Mcdonald Capital Investors Inc. CA owned approximately 0.18% of Regeneron Pharmaceuticals worth $124,799,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of REGN. Alps Advisors Inc. lifted its position in shares of Regeneron Pharmaceuticals by 71.0% during the 1st quarter. Alps Advisors Inc. now owns 530 shares of the biopharmaceutical company's stock worth $336,000 after buying an additional 220 shares during the last quarter. Rehmann Capital Advisory Group lifted its position in shares of Regeneron Pharmaceuticals by 112.9% during the 1st quarter. Rehmann Capital Advisory Group now owns 1,452 shares of the biopharmaceutical company's stock worth $921,000 after buying an additional 770 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its position in shares of Regeneron Pharmaceuticals by 4.4% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 3,190 shares of the biopharmaceutical company's stock worth $2,023,000 after buying an additional 135 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Regeneron Pharmaceuticals by 4.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 221,176 shares of the biopharmaceutical company's stock worth $139,484,000 after buying an additional 9,969 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after purchasing an additional 955 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 1.4%

Shares of REGN stock traded up $7.98 during trading hours on Friday, reaching $567.74. The company had a trading volume of 844,505 shares, compared to its average volume of 917,464. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The business has a fifty day simple moving average of $545.22 and a 200-day simple moving average of $620.50. The company has a market cap of $61.29 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business posted $9.55 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research note on Thursday. Finally, Citigroup decreased their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $823.54.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.